natgillin/translations-raw huggingface dataset:
Instructions on how to inject yourself (for patients with symptomatic anaemia caused by kidney disease, for patients receiving chemotherapy or adult patients scheduled for orthopaedic surgery only)
Upute za samostalnu primjenu injekcije (za bolesnike sa simptomatskom anemijom prouzročenom bolešću bubrega, za bolesnike koji primaju kemoterapiju ili odrasle bolesnike u kojih se planira samo ortopedski kirurški zahvat)
Instructions on how to open the child-resistant blister
Uputa kako otvoriti sigurnosne blistere za djecu
Instructions on how to prepare the solution with HEMANGIOL
Upute kako pripremiti otopinu s HEMANGIOL-om
Instructions on how to reconstitute, store and dispose of Hycamtin Reconstitution
Upute za rekonstituciju, čuvanje i odlaganje lijeka Hycamtin Rekonstitucija
INSTRUCTIONS ON HOW TO STORE AND DISPOSE OF ATRIANCE
UPUTE O ČUVANJU I ODLAGANJU LIJEKA ATRIANCE
Instructions on how to use LEVEMIR solution for injection in a FlexPen
Upute za uporabu LEVEMIR otopine za injekciju u brizgalici FlexPen
Instructions on how to use LEVEMIR solution for injection in InnoLet
Upute za uporabu LEVEMIR otopine za injekciju u brizgalici InnoLet
Instructions on how to use NovoSeven
Upute za uporabu lijeka NovoSeven
Instructions on how to use the syringe and adaptor are provided below:
Upute za uporabu štrcaljke i adaptera su u daljnjem tekstu:
Instructions on how to use Xolair are given in the section “Information for the healthcare professional”.
Upute o primjeni Xolaira navedene su u odlomku „Informacije za zdravstvene radnike“.
Instructions on injecting yourself with Inhixa
Upute kako samoinjicirati Inhixa
Instructions on injecting yourself with Nordimet
Upute kako sami sebi ubrizgati Nordimet
Instructions on management of adverse events based on monitoring and dose modifications or treatment withdrawal.
Upute za zbrinjavanje štetnih događaja na osnovu praćenja i prilagodba doze ili prestanak liječenja.
Instructions on the correct dose to be administered
upute o pravilnoj dozi koju treba primijeniti
Instructions on the rate of infusion are shown in Tables 5 and 6.
Smjernice za brzinu infuzije prikazane su u Tablicama 5 i 6.
Instructions on the safe use (to avoid the risk of overdosing), on storage (to avoid the risk of accidental exposure), and disposal of fentanyl buccal tablet
Upute o sigurnoj primjeni (kako bi se izbjegao rizik od predoziranja), o čuvanju (kako bi se izbjegao rizik od slučajnog izlaganja) i zbrinjavanju bukalnih tableta fentanila
Instructions on the use of the creatinine clearance slide ruler
Upute o uporabi pomične mjerke za izračun klirensa kreatinina
Instructions on the use of the creatinine clearance slide ruler
Upute za uporabu kliznog ravnala za izračun klirensa kreatinina.
Instructions on the use of the creatinine clearance slide ruler.
Upute o uporabi pomične mjerke za klirens kreatinina.
INSTRUCTIONS ON USE
UPUTE ZA PRIMJENU
INSTRUCTIONS ON USE
UPUTE ZA UPOTREBU
Instructions on use of the graduated syringe
Upute za uporabu kalibrirane štrcaljke
Instructions on when to discontinue the administration of HEMANGIOL
Upute kada prekinuti primjenu HEMANGIOL-a
Instructions overleaf 
Upute na poleđini 
Instructions precautions for disposal and other handling
Posebne mjere za zbrinjavanje i druga rukovanja lijekom
Instructions reinforcing that the indicated age range is 13-17 years and that aripiprazole is not recommended for use in patients below 13 years of age due to safety concerns
Upute u kojima se naglašava da je dobni raspon za ovu indikaciju između 13 i 17 godina i da se primjena aripiprazola ne preporučuje u bolesnika mlađih od 13 godina zbog sigurnosnih razloga
Instructions that the recommended dose is 10 mg/day and that enhanced efficacy at higher doses has not been demonstrated
Upute o tome da preporučena doza iznosi 10 mg/dan te da nije dokazana povećana djelotvornost kod primjene većih doza
Instructions to change and rotate the site of injection for each injection to avoid the development of lipohypertrophy.
Upute za promjenu i rotiranje mjesta injiciranja za svaku injekciju radi izbjegavanja razvoja lipohipertrofije.
Instructions to constitute the suspension:
Upute za pripremu suspenzije
Instructions to minimise the risk of exposure of blood and body fluids to close contacts for the duration of IMLYGIC treatment through 30 days after the last administration of IMLYGIC.
Upute za minimizaciju rizika od izlaganja krvi i tjelesnih tekućina osobama u neposrednoj blizini tijekom liječenja lijekom IMLYGIC i 30 dana nakon posljednje primjene lijeka IMLYGIC.
Instructions to provide patients and caregivers with the patient reminder card
Upute o davanju kartice s podsjetnikom za bolesnika bolesnicima i njegovateljima
Instructions to reconstitute the oral suspension
Upute za pripremu oralne suspenzije
Instructions to report the onset or worsening of snoring that may indicate an increase in growth of tonsils and/or adenoids following the beginning of treatment with INCRELEX.
Upute za prijavu početka ili pogoršanja hrkanja što može ukazivati na povećanje rasta tonzila i/ili adenoida nakon početka liječenja INCRELEXOM.
Instructions to stop pomalidomide immediately upon suspicion of pregnancy
upute za prekid uzimanja pomalidomida odmah nakon sumnje na trudnoću
Instrumentation
instrumentaciju
Insufficient circulation
nedostatna cirkulacija
Insufficient data are available for infants who have a post- conceptual age of less than 36 weeks.
Nedostatni su podaci za dojenčad postkoncepcijske dobi manje od 36 tjedana.
Insufficient data are available to make a recommendation for patients with a creatinine clearance < 20 ml/min.
Nema dovoljno podataka za preporuku doziranja u bolesnika s klirensom kreatinina <20 ml/min.
Insufficient data to recommend dosage
Nema dovoljno podataka da bi se dale
Insufficient data to recommend dosage adjustment.
Nedostatni podaci na osnovu kojih bi se preporučila prilagodba doze
Insufficient data to recommend dosage adjustment.
Nedostatni podatci na osnovu koji bi se preporučila prilagodba doze.
Insufficient data to recommend dosage adjustment.
Nedostatni podatci na osnovu kojih bi se preporučila prilagodba doze
Insufficient data to recommend dosage adjustment.
Nedostatni podatci na osnovu kojih bi se preporučila prilagodba doze.
Insufficient evidence
Nema dovoljno dokaza
Insufficient function of the kidneys, reduced production of urine, impaired or painful urination
nedostatna funkcija bubrega, smanjeno stvaranje mokraće, narušeno ili bolno mokrenje
Insufficient function of the kidneys, reduced production of urine, impaired or painful urination
nedostatna funkcija bubrega, smanjeno stvaranje mokraće, otežano ili bolno mokrenje
Insufficient numbers of older patients have been evaluated in clinical studies to determine whether they respond differently than younger patients.
Klinička su ispitivanja provedena na nedovoljnom broju starijih bolesnika da bi se mogla utvrditi razlika u odgovoru na liječenje od onoga u mlađih bolesnika.
insufficient production of thyroid hormone
nedovoljno stvaranje hormona štitnjače
Insufficient safety data are available for children below 18 years of age.
Nema dovoljno dostupnih podataka o sigurnosti primjene u djece mlađe od 18 godina.
INSULATED POLYURETHANE CONTAINER
IZOLIRANI POLIURETANSKI SPREMNIK
insulin
inzulin
Insulin absorption and hence the blood–glucose-lowering effect of a dose may vary from one injection area to another (e.g. the abdominal wall compared with the thigh).
Apsorpcija inzulina, a samim time i učinak doze na snižavanje razine glukoze u krvi, može se razlikovati od jednoga područja injiciranja do drugoga (npr. stijenka abdomena u usporedbi s bedrom).
Insulin administration should be temporarily stopped and the next dose of insulin adjusted appropriately.
Davanje inzulina bi privremeno trebalo obustaviti, a sljedeću dozu inzulina prilagoditi na odgovarajući način.
Insulin administration via the intraperitoneal route can cause the body to produce antibodies to insulin (substances that act against insulin).
Primjena inzulina u trbušnu šupljinu može uzrokovati stvaranje protutijela na inzulin (tvari koje djeluju protiv inzulina) u tijelu.
Insulin and sulphonylureas are known to cause hypoglycaemia.
Poznato je da inzulin i sulfonilureje izazivaju hipoglikemiju.
Insulin cartridge
Inzulinski uložak
Insulin cartridge
Uložak inzulina
insulin CV (%)
CV (%)
Insulin degludec (N26) (CV%)
Degludek inzulin (N26) (CV%)
Insulin degludec and insulin aspart binds specifically to the human insulin receptor and results in the same pharmacological effects as human insulin.
Degludek inzulin i aspart inzulin vežu se specifično na receptore humanog inzulina i imaju iste farmakološke učinke kao i humani inzulin.
Insulin degludec and liraglutide are extensively bound to plasma proteins (> 99% and > 98%, respectively).
Degludek inzulin i liraglutid u velikoj se mjeri vežu za proteine plazme (>99% odnosno >98%).
Insulin degludec is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed into the circulation leading to a flat and stable glucose-lowering-effect of insulin degludec with a low day-to- day variability in insulin action.
Degludek inzulin je bazalni inzulin koji tvori topive multiheksamere nakon supkutane injekcije, što rezultira stvaranjem depoa iz kojega se degludek inzulin neprestano i sporo apsorbira u cirkulaciju, što dovodi do ravnomjernog i stabilnog učinka degludek inzulina na snižavanje razine glukoze s malom varijabilnošću u djelovanju inzulina dan za danom.
Insulin degludec is slightly different from human insulin as it is absorbed more slowly and regularly by the body after an injection and it has a long duration of action.
Degludek inzulin se neznatno razlikuje od humanog inzulina jer ga tijelo apsorbira sporije i redovitije nakon injekcije i ima dugo razdoblje djelovanja.
insulin degludec – a long-acting basal insulin which lowers your blood sugar levels. liraglutide – a ‘GLP-1 analogue’ that helps your body make more insulin during meals and lowers the amount of sugar made by your body.
degludek inzulin – dugodjelujući bazalni inzulin koji snižava razine šećera u krvi liraglutid – ‘analog GLP-1’ koji pomaže Vašem tijelu stvoriti više inzulina tijekom obroka i smanjuje količinu šećera koje stvara Vaše tijelo.
Insulin degludec, maximum 50 units allowed
Degludek inzulin, najveća dopuštena doza: 50 jedinica
Insulin delivery device
Pomagalo za primjenu inzulina
Insulin detemir1
detemir inzulin1
Insulin dose (IU/day) at week 52b, 3
Doza inzulina (IU/dan) u 52. tjednub, 3
Insulin glargine
Glargin inzulin
Insulin glargine
Inzulin glargin
Insulin glargine (N27) (CV%)
Glargin inzulin (N27) (CV%)
Insulin glargine 100 units/ml was effective in managing diabetes in adults and children aged two years and above.
Inzulin glargin jačine 100 jedinica/ml bio je učinkovit u kontroli dijabetesa u odraslih i djece u dobi od dvije godine i starije.
Insulin glargine 100 units/ml was originally studied in 10 studies, in both type 1 diabetes (when the pancreas cannot produce insulin) and type 2 diabetes (when the body is unable to use insulin effectively).
Inzulin glargin od 100 jedinica/ml izvorno je ispitan u 10 ispitivanja kako za dijabetes tipa 1 (kada gušterača ne proizvodi inzulin) tako i za dijabetes tipa 2 (kada tijelo ne može učinkovito koristiti inzulin).
Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose and formulation of insulin glargine.
U najvećeg broja ispitanika inzulin glargin i metabolit M2 nisu bili mjerljivi, a kada i jesu pronađeni, njihova je koncentracija bila neovisna o primijenjenoj dozi i formulaciji inzulina glargina.
Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of insulin glargine.
U najvećeg broja ispitanika inzulin glargin i metabolit M2 nisu se mogli utvrditi, a kada su i utvrđeni, njihova je koncentracija bila neovisna o primijenjenoj dozi inzulina glargina.
Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of Lantus.
U najvećeg broja ispitanika inzulin glargin i metabolit M2 nisu se mogli utvrditi, a kada su i utvrđeni, njihova je koncentracija bila neovisna o primijenjenoj dozi lijeka Lantus.
Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of Toujeo.
U najvećeg broja ispitanika inzulin glargin i metabolit M2 nisu se mogli utvrditi, a kada su i utvrđeni, njihova je koncentracija bila neovisna o primijenjenoj dozi lijeka Toujeo.
Insulin glargine is a modified insulin, very similar to human insulin.
Inzulin glargin je modificirani inzulin, vrlo sličan ljudskom inzulinu.
Insulin glargine is metabolised into 2 active metabolites M1 and M2 (see section 5.2).
Inzulin glargin metabolizira se u 2 aktivna metabolita – M1 i M2 (vidjeti dio 5.2).
Insulin glargine is produced by recombinant DNA technology in Escherichia coli.
Inzulin glargin proizvodi se tehnologijom rekombinantne DNK na bakteriji Escherichia coli.
Insulin glargine SC use
inzulin glargin s.c. primjena
Insulin glargine, no limitation to dose
Glargin inzulin, bez ograničenja doze
Insulin glargine1
detemir inzulin1
Insulin glargine1
glargin inzulin1
Insulin glargine1
Inzulin glargin1
Insulin glargine3
glargin inzulin3
Insulin glulisine administered 15 minutes after starting the meal gives similar glycemic control as regular human insulin given 2 minutes before the meal (see figure 1).
Inzulin glulizin primijenjen 15 minuta nakon početka obroka ostvaruje slične rezultate kao i obični ljudski inzulin primijenjen 2 minute prije obroka (vidjeti sliku 1).
Insulin human SC use
humani inzulin s.c. primjena
Insulin Human Winthrop Basal 100 IU/ml suspension for injection in a cartridge
Insulin Human Winthrop Basal 100 IU/ml suspenzija za injekciju u ulošku
Insulin Human Winthrop Basal 100 IU/ml suspension for injection in a cartridge Insulin human
Insulin Human Winthrop Basal 100 IU/ml suspenzija za injekciju u ulošku humani inzulin
Insulin Human Winthrop Basal 100 IU/ml suspension for injection in a vial
Insulin Human Winthrop Basal 100 IU/ml suspenzija za injekciju u bočici
Insulin Human Winthrop Basal 100 IU/ml suspension for injection in a vial Insulin human
Insulin Human Winthrop Basal 100 IU/ml suspenzija za injekciju u bočici humani inzulin
Insulin Human Winthrop Basal 100 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Basal 100 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Basal 40 IU/ml suspension for injection in a vial
Insulin Human Winthrop Basal 40 IU/ml suspenzija za injekciju u bočici
Insulin Human Winthrop Basal 40 IU/ml suspension for injection in a vial Insulin human
Insulin Human Winthrop Basal 40 IU/ml suspenzija za injekciju u bočici humani inzulin
Insulin Human Winthrop Basal 40 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Basal 40 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Basal may be mixed with all insulin human formulations, but not with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Basal može se miješati sa svim formulacijama humanog inzulina, ali ne i s onima koji su posebno namijenjeni za primjenu u inzulinskim pumpama.
Insulin Human Winthrop Basal must not be mixed with any other insulin or with insulin analogues.
Insulin Human Winthrop Basal se ne smije miješati s drugim inzulinima niti inzulinskim analozima.
Insulin Human Winthrop Basal must not be used if this cannot be achieved, i.e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulin Human Winthrop Basal ne smije se upotrijebiti ako se to ne može postići, tj. ako suspenzija, primjerice, ostane bistra ili ako se u inzulinu nalaze grudice, čestice ili pahuljice koje se mogu slijepiti za stijenke ili dno uloška.
Insulin Human Winthrop Basal SoloStar 100 IU/ml suspension for injection in a pre-filled pen Insulin human
Insulin Human Winthrop Basal SoloStar 100 IU/ml suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Insulin Human Winthrop Basal SoloStar 100 IU/ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Basal SoloStar 100 IU/ml suspenzija za injekciju u napunjenoj brizgalici
Insulin Human Winthrop Basal SoloStar 100 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Basal SoloStar 100 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Basal with alcohol.
Insulin Human Winthrop Basal s alkoholom
Insulin Human Winthrop Comb 15 100 IU/ml suspension for injection in a cartridge
Insulin Human Winthrop Comb 15 100 IU/ml suspenzija za injekciju u ulošku
Insulin Human Winthrop Comb 15 100 IU/ml suspension for injection in a cartridge Insulin human
Insulin Human Winthrop Comb 15 100 IU/ml suspenzija za injekciju u ulošku humani inzulin
Insulin Human Winthrop Comb 15 100 IU/ml suspension for injection in a vial
Insulin Human Winthrop Comb 15 100 IU/ml suspenzija za injekciju u bočici
Insulin Human Winthrop Comb 15 100 IU/ml suspension for injection in a vial Insulin human
Insulin Human Winthrop Comb 15 100 IU/ml suspenzija za injekciju u bočici humani inzulin
Insulin Human Winthrop Comb 15 100 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Comb 15 100 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Comb 15 40 IU/ml suspension for injection in a vial
Insulin Human Winthrop Comb 15 40 IU/ml suspenzija za injekciju u bočici
Insulin Human Winthrop Comb 15 40 IU/ml suspension for injection in a vial Insulin human
Insulin Human Winthrop Comb 15 40 IU/ml suspenzija za injekciju u bočici humani inzulin
Insulin Human Winthrop Comb 15 40 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Comb 15 40 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Comb 15 may be mixed with all insulin human formulations, but not with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Comb 15 može se miješati sa svim formulacijama humanog inzulina, ali ne i s onima koji su posebno namijenjeni za primjenu u inzulinskim pumpama.
Insulin Human Winthrop Comb 15 must not be administered intravenously and must not be used in infusion pumps or external or implanted insulin pumps.
Insulin Human Winthrop Comb 15 ne smije se primijeniti intravenski i ne smije se primjenjivati u infuzijskim pumpama niti u vanjskim ili ugrađenim inzulinskim pumpama.
Insulin Human Winthrop Comb 15 must not be used if this cannot be achieved, i.e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulin Human Winthrop Comb 15 ne smije se upotrijebiti ako se to ne može postići, tj. ako suspenzija, primjerice, ostane bistra ili ako se u inzulinu nalaze grudice, čestice ili pahuljice koje se mogu slijepiti za stijenke ili dno uloška.
Insulin Human Winthrop Comb 15 must not be used if this cannot be achieved, i.e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulin Human Winthrop Comb 15 se ne smije upotrijebiti ako se to ne može postići, tj. ako suspenzija, primjerice, ostane bistra ili ako se u inzulinu nalaze grudice, čestice ili pahuljice koje se mogu slijepiti za stijenke ili dno uloška.
Insulin Human Winthrop Comb 15 SoloStar 100 IU/ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 15 SoloStar 100 IU/ml suspenzija za injekciju u napunjenoj brizgalici
Insulin Human Winthrop Comb 15 SoloStar 100 IU/ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb SoloStar 15 100 IU/ml suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Insulin Human Winthrop Comb 15 SoloStar 100 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Comb 15 SoloStar 100 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Comb 25 100 IU/ml suspension for injection in a cartridge
Insulin Human Winthrop Comb 25 100 IU/ml suspenzija za injekciju u ulošku
Insulin Human Winthrop Comb 25 100 IU/ml suspension for injection in a cartridge Insulin human
Insulin Human Winthrop Comb 25 100 IU/ml suspenzija za injekciju u ulošku humani inzulin
Insulin Human Winthrop Comb 25 100 IU/ml suspension for injection in a vial
Insulin Human Winthrop Comb 25 100 IU/ml suspenzija za injekciju u bočici
Insulin Human Winthrop Comb 25 100 IU/ml suspension for injection in a vial Insulin human
Insulin Human Winthrop Comb 25 100 IU/ml suspenzija za injekciju u bočici humani inzulin
Insulin Human Winthrop Comb 25 100 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Comb 25 100 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Comb 25 40 IU/ml suspension for injection in a vial
Insulin Human Winthrop Comb 25 40 IU/ml suspenzija za injekciju u bočici
Insulin Human Winthrop Comb 25 40 IU/ml suspension for injection in a vial Insulin human
Insulin Human Winthrop Comb 25 40 IU/ml suspenzija za injekciju u bočici humani inzulin
Insulin Human Winthrop Comb 25 40 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Comb 25 40 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Comb 25 alcohol
Insulin Human Winthrop Comb 25 s alkoholom
Insulin Human Winthrop Comb 25 may be mixed with all insulin human formulations, but not with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Comb 25 može se miješati sa svim formulacijama humanog inzulina, ali ne i s onima koji su posebno namijenjeni za primjenu u inzulinskim pumpama.
Insulin Human Winthrop Comb 25 must not be administered intravenously and must not be used in infusion pumps or external or implanted insulin pumps.
Insulin Human Winthrop Comb 25 ne smije se primijeniti intravenski i ne smije se primjenjivati u infuzijskim pumpama niti u vanjskim ili ugrađenim inzulinskim pumpama.
Insulin Human Winthrop Comb 25 must not be used if this cannot be achieved, i.e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulin Human Winthrop Comb 25 ne smije se upotrijebiti ako se to ne može postići, tj. ako suspenzija, primjerice, ostane bistra ili ako se u inzulinu nalaze grudice, čestice ili pahuljice koje se mogu slijepiti za stijenke ili dno uloška.
Insulin Human Winthrop Comb 25 must not be used if this cannot be achieved, i.e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulin Human Winthrop Comb 25 se ne smije upotrijebiti ako se to ne može postići, tj. ako suspenzija, primjerice, ostane bistra ili ako se u inzulinu nalaze grudice, čestice ili pahuljice koje se mogu slijepiti za stijenke ili dno uloška.
Insulin Human Winthrop Comb 25 SoloStar 100 IU/ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 25 SoloStar 100 IU/ml suspenzija za injekciju u napunjenoj brizgalici
Insulin Human Winthrop Comb 25 SoloStar 100 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Comb 25 SoloStar 100 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Comb 30 100 IU/ml suspension for injection in a cartridge
Insulin Human Winthrop Comb 30 100 IU/ml suspenzija za injekciju u ulošku
Insulin Human Winthrop Comb 30 100 IU/ml suspension for injection in a cartridge Insulin human
Insulin Human Winthrop Comb 30 100 IU/ml suspenzija za injekciju u ulošku humani inzulin
Insulin Human Winthrop Comb 30 100 IU/ml suspension for injection in a vial
Insulin Human Winthrop Comb 30 100 IU/ml suspenzija za injekciju u bočici